Top Story

Adverse events decrease with DPP-IV, SGLT2 inhibitors in type 2 diabetes

March 29, 2017

The risks for all-cause mortality, cardiovascular disease and severe hypoglycemia are reduced for adults with type 2 diabetes prescribed DPP-IV inhibitors or the SGLT2 inhibitor dapagliflozin compared vs. insulin alone, study data from Sweden show.

Thomas Nyström, MD, of the unit for diabetes research, division of internal medicine, department of clinical science and education at the Karolinska Institute in Sweden, and colleagues evaluated data on adults with type 2 diabetes who filled a first-time prescription for a DPP-IV inhibitor or dapagliflozin (Farxiga, AstraZeneca), the only SGLT2 inhibitor available in Sweden during the study period (oral drug group, n = 10,879), or for insulin (insulin group, n = 10,879) between July 1, 2013, and Dec. 31, 2014, to determine the effect of the drugs on all-cause mortality, CVD and severe hypoglycemia. Median follow-up times were 1.51 years in the oral drug group and 1.53 years in the insulin group.

In the Journals

Type 1 diabetes associated with higher risk for ischemic, hemorrhagic stroke

March 23, 2017
Compared with the general population, patients with type 1 diabetes with or without maintaining target HbA1c levels were at increased risk for ischemic and hemorrhagic…
In the Journals Plus

Statin use increases type 2 diabetes risk

March 22, 2017
Adults treated with statin therapy are at higher risk for developing type 2 diabetes vs. those not prescribed statin therapy, according to a meta-analysis of…
Meeting News

EXCEL: PCI may be acceptable in patients with diabetes, less complex left main CAD

March 17, 2017
WASHINGTON, D.C. — Three-year data from the EXCEL trial indicate that PCI with an everolimus-eluting stent may be acceptable or even preferable to CABG for…
In the Journals Plus

New ADA standards highlight CV outcomes trials, psychosocial health, bariatric surgery

December 16, 2016
The American Diabetes Association’s updated 2017 Standards of Medical Care in Diabetes includes several new updates that will affect patient…

Meeting News

Cardiotoxicity from anthracycline chemotherapy worse in patients with diabetes

December 13, 2016
Among patients being treated for breast cancer, lymphoma or gastric cancer with anthracycline-based chemotherapy, cardiotoxicity from the treatment…

In the Journals

CHD incidence decreases, but association with most risk factors unchanged

December 2, 2016
Incidence of CHD declined nearly 20% from 1983 to 2011, but its association with several known risk factors has not changed over time, according to a…

FDA News

FDA approves expanded indication for empagliflozin to reduce CV death in type 2 diabetes

December 2, 2016
The FDA approved a new indication for the SGLT2 inhibitor empagliflozin to reduce the risk for cardiovascular death in adult patients with type 2…

In the Journals Plus

Hormonal contraceptives may not increase thromboembolism risk in diabetes

December 2, 2016
The risk for thromboembolism among women with type 1 and type 2 diabetes may not be increased with use of hormonal contraception, study data…

In the Journals

Two genetic variants may reduce CV event risk, increase diabetes risk

December 1, 2016
Variants of the PCSK9 and HMGCR genes linked to lower LDL were associated with protection from CV events and increased risk for diabetes in certain…

In the Journals Plus

Higher insulin doses not associated with increased mortality, CV risk in type 2 diabetes

November 23, 2016
For adults with type 2 diabetes initiating insulin therapy, there is no dose-response relationship between the amount of daily insulin and all-cause…

In the Journals Plus

Polyphenol intake confers cardiometabolic benefit in type 2 diabetes

November 18, 2016
Older adults with type 2 diabetes who consume greater quantities of foods or beverages containing polyphenols showed a modestly improved…

Meeting News

Low-dose aspirin shows neutral CV benefit, increases bleeding risk in type 2 diabetes

November 16, 2016
NEW ORLEANS — In patients with type 2 diabetes, low-dose aspirin therapy did not affect the risk for CV events, but increased risk for…

Meeting NewsPerspective

Statin use confers better outcomes after cardiac arrest, particularly in patients with diabetes

November 14, 2016
NEW ORLEANS — Among patients with out-of-hospital cardiac arrest, those taking statins had better survival outcomes compared with those who did…

More Headlines »